2. Disease Areas
  3. Cancer Blood or Cardio-cerebrovascular Disease
  4. Leukemia/Lymphoma/Myeloma Blood Disease
  5. Leukemia/Lymphoma/Myeloma
  6. Multiple Myeloma

Multiple Myeloma

Multiple myeloma is a rare blood cancer characterized by the uncontrolled proliferation of abnormal plasma cells in the bone marrow, leading to bone damage, anemia, fatigue, and kidney dysfunction due to excess antibody production. It results from the transformation of healthy plasma cells into malignant ones that crowd out normal blood cell production, causing symptoms such as persistent bone pain, weakness, and shortness of breath. The disease may present as multiple tumors throughout the body, requiring careful monitoring and management. While incurable, treatments including chemotherapy, radiation, and stem cell transplantation can help control progression and alleviate symptoms.

Multiple Myeloma (56):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P9980
    Belantamab 2061894-48-0 99.90%
    Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma.
    Belantamab
  • HY-154812
    Gintemetostat 2604513-16-6 99.81%
    Gintemetostat (KTX-1001) is an orally active, highly specific NSD2/MMSET histone methyltransferase inhibitor with human NSD2 IC50 values ranging 0.460-2.17 nM and NSD2 SET domain IC50 of 2.32 nM and Kd values ranging 6.3-70.4 nM.Gintemetostat reduces H3K36me2 levels, impairs multiple myeloma cell adhesion and colony formation, enhances cytotoxicity, boosts T-cell activation, and sensitizes resistant multiple myeloma cells to other agents.Gintemetostat can be used for the research of multiple myeloma and relapsed and refractory multiple myeloma.
    Gintemetostat
  • HY-NP138
    NP-OVAL (Ovalbumin)
    NP-OVAL (Ovalbumin) is a complex formed by 4-Hydroxy-3-nitrophenylacetyl (NP, a hapten) with Ovalbumin (OVAL, a carrier protein). NP-OVAL (Ovalbumin) can induce specific immune responses and NP-specific antibodies production. NP-OVAL (Ovalbumin) can accelerate the construction of multiple myeloma models.
    NP-OVAL (Ovalbumin)
  • HY-B0657A
    Clodronic acid disodium salt 22560-50-5 99.80%
    Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis.
    Clodronic acid disodium salt
  • HY-B0657
    Clodronic acid 10596-23-3 99.41%
    Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis.
    Clodronic acid
  • HY-107194
    NSC12 102586-30-1 99.27%
    NSC12 is an orally active pan-FGF trap. NSC12 inhibits the interaction between FGF2/FGFR. NSC12 suppresses the phosphorylation of FGFR3. NSC12 reduces c-Myc levels, induces DNA damage, triggers the cleavage of Caspase 3, and promotes ROS production. NSC12 exhibits anticancer activity against lung cancer and multiple myeloma.
    NSC12
  • HY-W1135319
    SB-405483 99.33%
    SB-405483 is a CRBN orthosteric ligand bindign enhancer. SB-405483 potentiates degradation of CRBN substrates including CK1α, Wee1, IKZF1/3. SB-405483 stabilizes CRBN and reduces CRBN autoubiquitination. SB-405483 can be used for the research of cancer, such as multiple myeloma and acute myeloid leukemia.
    SB-405483
  • HY-115590
    JP-11646 1902983-63-4 98.74%
    JP-11646 is a pan-PIM inhibitor with increased potency against PIM2 (IC50 = 0.5 nM). JP11646 is freely reversible and ATP non-competitive. JP-11646 results in a decrease of PIM1, 2, and 3 mRNA. JP-11646 can effectively inhibit cell viability in small cell lung cancer (SCLC) and large cell neuroendocrine carcinomas of the lung (LCNEC). JP-11646 can cause a decrease in p-4EBP-1 protein, increasing the cleavage of caspases while decreasing caspase-3. JP-11646 induces apoptosis or necroptosis in cells. JP-11646 leads to reductions in MYC paralogs. JP-11646 can be used for the study of SCLC, LCNEC, human acute leukemia (AML), multiple myeloma (MM), and triple-negative breast cancer (TNBC).
    JP-11646
  • HY-180177
    PROTAC BLIMP-1 degrader-1
    PROTAC BLIMP-1 degrader-1 (Compound 49) is a PROTAC-based BLIMP-1 degrader. PROTAC BLIMP-1 degrader-1 promotes the ubiquitination and degradation of BLIMP-1 and can be used in research on myeloproliferative tumors.
    PROTAC BLIMP-1 degrader-1
  • HY-128586A
    TAS4464 hydrochloride 1848959-11-4 98.91%
    TAS4464 hydrochloride is a long-acting, highly selective covalent inhibitor targeting NEDD8-activating enzyme (NAE) (IC50=0.955 nM), and also inhibits CAII with an IC50 of 0.73 μM, which is less potent than MLN4924 (HY-70062). The IC50 values of TAS4464 hydrochloride against other E1 enzymes UAE and SAE are 449 nM and 1280 nM, respectively. TAS4464 hydrochloride targets NEDD8 in an ATP-dependent manner to inhibit NAE, blocks the neddylation pathway, causes accumulation of CRL ubiquitin ligase substrates (such as CDT1, p27, phosphorylated IκBα), and further induces tumor cell apoptosis. TAS4464 hydrochloride exhibits antiproliferative and cytotoxic effects, and has broad-spectrum antitumor activity against various hematologic and solid tumor cell lines as well as patient-derived tumor cells. TAS4464 hydrochloride has a wide therapeutic window, without obvious toxicity. TAS4464 hydrochloride can be used in the research of hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.) and solid tumors (small cell lung cancer, colorectal cancer, sarcoma, endometrial cancer, ovarian cancer, etc.).
    TAS4464 hydrochloride
  • HY-13032B
    Molibresib besylate 1895049-20-3
    Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors.
    Molibresib besylate
  • HY-P991155
    Ramantamig 2988886-91-3
    Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma.
    Ramantamig
  • HY-P990095
    Vonsetamig 2408319-33-3
    Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and CD3. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma.
    Vonsetamig
  • HY-W008951
    Ethylenediaminetetra(methylenephosphonic acid) 1429-50-1 99.9%
    Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers.
    Ethylenediaminetetra(methylenephosphonic acid)
  • HY-119264
    PRLX-93936 903499-49-0 98.31%
    PRLX-93936 is a molecular Glues that binds to and reprograms the TRIM21 ubiquitin ligase to degrade nuclear pore complexes. PRLX-93936 binds to TRIM21, forms a ternary complex with TRIM21 and NUP98, and mediates the ubiquitination and proteasomal degradation of NUP98 and other nuclear pore complex proteins. PRLX-93936 induces the loss of short-lived cytoplasmic mRNA transcripts, triggers cancer cell apoptosis (Apoptosis), and inhibits the activated Ras pathway. PRLX-93936 inhibits HIF-1 under hypoxic conditions (IC50 = 0.09 μM in cell-based reporter gene assay). PRLX-93936 suppresses tumor growth in mouse models and improves survival rates in mouse models of multiple myeloma. PRLX-93936 is applicable to research related to pancreatic cancer and multiple myeloma.
    PRLX-93936
  • HY-128360
    dMCL1-2 2351218-88-5 99.29%
    dMCL1-2 is a potent, selective MCL1 PROTAC degrader based on a Cereblon ligand, with a KD value of 30 nM for binding to MCL1. dMCL1-2 induces ubiquitination and degradation of MCL1. dMCL1-2 degrades MCL1, cleaves Caspase-3, and induces Apoptosis. dMCL1-2 can be used in research related to multiple myeloma.
    dMCL1-2
  • HY-148105
    DS12881479 2373065-59-7 99.63%
    DS12881479 is a selective non-ATP-competitive MNK1 inhibitor with an IC50 value of 387 nM. DS12881479 stabilizes MNK1 in its autoinhibited DFD-out conformation, blocks eIF4E phosphorylation, suppresses tumor cell proliferation and induces weak apoptosis. DS12881479 also inhibits FLT3 and DYRK1a kinase activity at high concentrations. DS12881479 can be used for the research of cancer, such as leukemia.
    DS12881479
  • HY-185002
    BCMA CAR mRNA
    BCMA CAR mRNA can express the CAR protein targeting human BCMA. BCMA CAR mRNA can trigger the transient expression of CAR, enabling T cells to be targeted without the need for permanent genetic modification. BCMA is a member of the tumor necrosis factor receptor superfamily 17 (TNFRSF17), also known as B-cell maturation antigen (CD269), which promotes B-cell survival and plays a role in regulating humoral immunity. BCMA is highly expressed in multiple myeloma and is a biomarker for the diagnosis of multiple myeloma.
    BCMA CAR mRNA
  • HY-160696
    ORIC-533 2641306-62-7
    ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka=0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with Daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8+ T cell infiltration and inhibits tumor growth in vivo.
    ORIC-533
  • HY-P992483
    VIS832
    VIS832 is an anti-CD138 monoclonal antibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma.
    VIS832